Comment on: ''Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting [Beta]-Agonists'

The re-analysis of study data using the revised transition matrices predicted that tiotropium add-on therapy reduced exacerbations and improved asthma control with an incremental cost-effectiveness ratio of £28,383 (obtained at 2012 prices) per quality-adjusted life-year (QALY) gained, which is with...

Full description

Saved in:
Bibliographic Details
Published inApplied health economics and health policy Vol. 14; no. 1; p. 117
Main Authors Samuelsen, Carl, Bateman, Eric D, Pavord, Ian, Lloyd, Adam, Baldwin, Mike, Esser, Dirk
Format Journal Article
LanguageEnglish
Published Auckland Springer Nature B.V 01.02.2016
Subjects
Asthma
Colleges & universities
Cost analysis
Drug dosages
Employees
Medicine
Pharmaceutical industry
Sensitivity analysis
Willingness to pay
Online AccessGet full text

Cover

More Information
Summary:The re-analysis of study data using the revised transition matrices predicted that tiotropium add-on therapy reduced exacerbations and improved asthma control with an incremental cost-effectiveness ratio of £28,383 (obtained at 2012 prices) per quality-adjusted life-year (QALY) gained, which is within the commonly accepted £20,000-£30,000 per QALY gained willingness-to-pay threshold used in the UK [2]. The results of these additional sensitivity analyses show that tiotropium may be cost-effective when added to usual care in patients whose asthma remains uncontrolled despite treatment with high-dose ICS plus LABA, irrespective of the modelling method used, and so provides additional confidence that the conclusions presented in our published manuscript are valid.
ISSN:1175-5652
1179-1896
DOI:10.1007/s40258-015-0215-0